Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MDS Follows Two Misdiagnoses

    ... erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , (Vidaza®) and deferoxamine (Desferal®). My hemoglobin ... so far this year which is more than usual for me and my last azacitidine (Vidaza®) treatment in June didn't seem to have much benefit. ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.

  2. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

    ... and response. Treatment consisted on a combination of azacitidine and vorinostat. Thirty patients (16 with MDS, 14 with AML) were ... the study and treated 79 additional patients: 27 with azacitidine (AZA) and 52 with azacitidine and vorinostat (AZA+V). Median ...

    Research Article last updated 11/28/2016 - 11:15am.

  3. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... , alone or in combination with ESAs; oral azacitidine ; and new molecules such as the activin receptor type II ligand ...

    Research Article last updated 12/09/2016 - 2:50pm.

  4. MDS/AML patients benefit from novel study

    ... 109 patients with AML and MDS undergoing treatment with azacitidine (AZA) and vorinostat. Research results were presented Dec. 3 at ...

    Article last updated 12/08/2016 - 2:34pm.

  5. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), ... AND METHODS: Patients received 1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle 1, followed by oral ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Effectiveness of azacitidine in higher-risk myelodysplastic syndromes

    ...

    Research Article last updated 06/23/2016 - 9:31am.

  7. Azacitidine in lower-risk myelodysplastic syndromes.

    ... 1, 2009 Azacitidine is the first agent to significantly prolong overall survival ... (MDS). Here, we review currently available data on azacitidine treatment in lower-risk MDS. In a phase III study, a subset of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  8. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may complement each other by ... . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, lenalidomide’s ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Azacitidine in the management of patients with myelodysplastic syndromes.

    ... of irreversible DNA methlytransferase inhibitors such as azacitidine was investigated with promising outcomes in the treatment of MDS. Azacitidine was initially approved in the USA by the Food and Drug ... in the AZA-001 study of patients with higher-risk MDS. Azacitidine has demonstrated significant and clinically meaningful prolongation ...

    Research Article last updated 05/14/2013 - 2:48pm.

  10. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents.

    ... a rationale for using hypomethylating agents such as azacitidine . Growing evidence suggests that azacitidine may reverse epigenetic gene silencing at specific genomic targets. ...

    Research Article last updated 10/11/2011 - 5:58pm.